Korro Announces Oversubscribed $85 Million Private Placement

Core Viewpoint - Korro Bio, Inc. has announced a private investment in public equity (PIPE) financing expected to generate approximately $85 million in gross proceeds, aimed at advancing its RNA editing platform and extending its cash runway into the second half of 2028 [1][4][9] Financing Details - The PIPE financing is led by Venrock Healthcare Capital Partners, with participation from both new and existing investors including ADAR1 Capital Management and New Enterprise Associates [2] - Korro is selling 4,501,928 shares of common stock at $11.11 per share and pre-funded warrants for 3,148,836 shares at $11.109 each, with an exercise price of $0.001 per share [3] Use of Proceeds - The net proceeds will support clinical development milestones for key pipeline assets, including KRRO-121 and the GalNAc-conjugated AATD program, and will also be used for working capital and general corporate purposes [4][9] - The funding will enable advancements in Korro's longevity and liver health program targeting the AMPKγ1 pathway [4] Company Overview - Korro Bio is focused on developing a new class of genetic medicines through RNA editing for both rare and prevalent diseases, utilizing its proprietary OPERA platform [8][10] - The company aims to enhance the precision and tunability of genetic medicines, potentially improving specificity and long-term tolerability [10]